Nakano M, Iwamuro S, Fujii H, Kondoh I
Department of Urology, Kanagawa Cancer Center Hospital.
Hinyokika Kiyo. 1988 Jun;34(6):983-6.
Seven patients with recurrent superficial bladder tumors were treated by vesical and intradermal administration of BCG. All of these patients have had recurrence more than 2 times. BCG instillation was performed every weeks for 6 weeks after transurethral resection of bladder tumor. A suspension containing 120 mg BCG in 40 ml normal saline was instilled intravesically. BCG was administered into alternate upper thighs using a multiple puncture apparatus. Statistical analysis of bladder tumor in our hospital revealed the second recurrence rate to be 73.2%. The reduction of tumor recurrence rate of BCG treated patients was 43.0%. The reduction of tumor recurrence by BCG treatment was statistically significant, compared to other treatments. It seemed that patients with severe side effects such as bladder tenesmus and urinary infection, have a long tumor-free period. Therefore, we suggest that the reactive inflammation in bladder during BCG treatment plays an important role.
7例复发性浅表膀胱肿瘤患者接受了卡介苗膀胱内及皮内注射治疗。所有这些患者均复发2次以上。经尿道膀胱肿瘤切除术后，每周进行1次卡介苗灌注，共6周。将含120mg卡介苗的40ml生理盐水混悬液膀胱内灌注。使用多点穿刺装置将卡介苗注射到双侧大腿上部。我院对膀胱肿瘤的统计分析显示，第二次复发率为73.2%。卡介苗治疗患者的肿瘤复发率降低了43.0%。与其他治疗相比，卡介苗治疗导致的肿瘤复发率降低具有统计学意义。似乎有严重副作用如膀胱痉挛和尿路感染的患者，无瘤生存期较长。因此，我们认为卡介苗治疗期间膀胱内的反应性炎症起重要作用。
